乳腺癌P-gp、LRP、GST-π、TOPO-Ⅱ的表达及其与术前化疗的关系

Expressions of P-gp,LRP, GST-π and TOPO Ⅱ in Breast Cancer and It's Relation with Neoadjuvant Chemotherapy

目的 :探讨P gp、LRP、GST π、TOPO Ⅱ在乳腺癌中的表达以及术前化疗对乳腺癌多药耐药的影响及其临床意义。方法 :采用免疫组织化学S P法 ,对 18例术前曾用化疗和 70例术前未用化疗的 88例乳腺癌组织检测P gp、LRP、GST π、TOPO Ⅱ的表达。结果 :88例乳腺癌中P gp、LRP、GST π、TOPO Ⅱ的阳性率分别为 4 2 .0 %、5 3.4 %、4 8.9%、4 0 .9%。术前应用化疗的病人乳腺癌组织P gp、LRP、GST π三者阳性表达率均较未用化疗的病人高。P gp和LRP差异有显著性 (P <0 .0 5 ) ,而GST π差异无显著性 (P >0 .0 5 ) ,TOPO Ⅱ有化疗史的病人比无化疗史的病人低 ,但差异无显著性 (P >0 .0 5 )。结论 :P gp、LRP、GST π、TOPO Ⅱ的耐药机制各不相同 ,同时检测P gp、LRP、GST π、TOPO Ⅱ等多种导致多药耐药的因素 ,对乳腺癌化疗有重要的指导意义。

Objective To investigate the relationship between expression of P-gp, LRP, GST-πand TOPO-Ⅱ and neoadjuvant chemotherapy in breast cancer.Methods By using immunohistochemical S-P method,the expressions of P-gp,LRP, GST-π and TOPO-Ⅱ were detected in l8 cases treated by chemotherapy before surgery and 70 cases of no n-chemotherapy Of breast cancer. Results The positive rates of P-gp, LRP, GST-π and TOPO-Ⅱ were 42.0 %,53.4 %,48.9 %,40.9 % respectively in 88 cases of breast cancer.The P-gp and LRP positive expressions in cases of non-Chcmothcrapy were 35.7 % and 47.1 % respcctively,but it increased significantly in the neoadjuvant chemotherapy group(P<0.05).Conclusions combining examination of P-gp,LRP, GST-π and TOPO-Ⅱ may have an instmctive significant for Chemotherapy of breast cancer.